Dynavax Technologies Corporation - Common Stock (NQ:DVAX)

15.50 UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dynavax Technologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study ↗

August 21, 2025

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Via Benzinga

Dynavax (DVAX) Q2 Revenue Jumps 29% ↗

August 07, 2025

Via The Motley Fool

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom

June 09, 2025

From Deep Track Capital, LP

Via Business Wire

Glass Lewis Recommends Shareholders Support Deep Track’s Case for Board Change at Dynavax Technologies

June 04, 2025

From Deep Track Capital, LP

Via Business Wire

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Deep Dive Into Dynavax Technologies Stock: Analyst Perspectives (4 Ratings) ↗

February 21, 2025

Via Benzinga

Earnings Scheduled For February 20, 2025 ↗

February 20, 2025

Via Benzinga

Deep Track Capital Comments on ISS Recommendation

May 23, 2025

From Deep Track Capital, LP

Via Business Wire

Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting

May 15, 2025

From Deep Track Capital, LP

Via Business Wire

Breaking Down Dynavax Technologies: 5 Analysts Share Their Views ↗

May 07, 2025

Via Benzinga

Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗

May 07, 2025

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.

Via Benzinga

Insights into Dynavax Technologies's Upcoming Earnings ↗

November 06, 2024

Via Benzinga

Assessing Dynavax Technologies: Insights From 4 Financial Analysts ↗

August 08, 2024

Via Benzinga

Deep Track Capital Releases Investor Presentation on Dynavax Technologies

May 06, 2025

From Deep Track Capital, LP

Via Business Wire

Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

April 21, 2025

From Deep Track Capital, LP

Via Business Wire

Where Dynavax Technologies Stands With Analysts ↗

April 17, 2025

Via Benzinga

Deep Track Capital Comments on Dynavax Technologies’ Rejection of Most Recent Settlement Offer

April 16, 2025

From Deep Track Capital, LP

Via Business Wire

Evaluating DYNAVAX TECHNOLOGIES CORP (NASDAQ:DVAX) using Mark Minervini’s winning stock formula ↗

March 31, 2025

A fundamental and technical analysis of (NASDAQ:DVAX): Why DYNAVAX TECHNOLOGIES CORP (NASDAQ:DVAX) is Poised for High Growth.

Via Chartmill

Deep Track Capital Sends Letter to Dynavax Technologies’ Board of Directors

March 10, 2025

From Deep Track Capital, LP

Via Business Wire

Dynavax Technologies (DVAX) Q4 2024 Earnings Call Transcript ↗

February 20, 2025

DVAX earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies’ Board of Directors at 2025 Annual Meeting

February 19, 2025

From Deep Track Capital, LP

Via Business Wire

Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 15 ↗

February 15, 2025

What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 10-14, 2025.

Via Talk Markets

Topics Stocks / Equities

Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty ↗

February 11, 2025

Goldman Sachs downgraded Dynavax to Sell, citing increased competition in the shingles vaccine market and uncertainty over hepatitis B revaccination demand.

Via Benzinga

This Columbus McKinnon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

February 11, 2025

Via Benzinga

Dynavax Technologies (DVAX) Q3 2024 Earnings Call Transcript ↗

November 07, 2024

DVAX earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Glancy Prongay & Murray LLP Announces Investigation of Dynavax Technologies Corporation (DVAX)

November 06, 2024

From Glancy Prongay & Murray LLP

Via Business Wire

Lantheus Appoints Julie Eastland as New Board Member

September 05, 2024

From Lantheus Holdings, Inc.

Via GlobeNewswire

Dynavax Technologies (DVAX) Q2 2024 Earnings Call Transcript ↗

August 06, 2024

DVAX earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

DVAX Stock Earnings: Dynavax Technologies Beats EPS, Misses Revenue for Q2 2024 ↗

August 06, 2024

DVAX stock results show that Dynavax Technologies beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.